Abstract
Primary pulmonary hypertension is a progressive and often fatal disorder in humans that results from an increase in pulmonary blood pressure associated with abnormal vascular proliferation. Dexfenfluramine increases the risk of pulmonary hypertension in humans, and its active metabolite is a selective serotonin 5-hydroxytryptamine 2B (5-HT2B) receptor agonist. Thus, we investigated the contribution of the 5-HT2B receptor to the pathogenesis of pulmonary hypertension. Using the chronic-hypoxic-mouse model of pulmonary hypertension, we found that the hypoxia-dependent increase in pulmonary blood pressure and lung remodeling are associated with an increase in vascular proliferation, elastase activity and transforming growth factor-β levels, and that these parameters are potentiated by dexfenfluramine treatment. In contrast, hypoxic mice with genetically or pharmacologically inactive 5-HT2B receptors manifested no change in any of these parameters. In both humans and mice, pulmonary hypertension is associated with a substantial increase in 5-HT2B receptor expression in pulmonary arteries. These data show that activation of 5-HT2B receptors is a limiting step in the development of pulmonary hypertension.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rabinovitch, M. Pulmonary hypertension: updating a mysterious disease. Cardiovasc. Res. 34, 268–272 (1997).
Rubin, L.J. Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension. Pediatr. Pulmonol. Suppl. 18, 194–197 (1999).
Loscalzo, J. Genetic clues to the cause of primary pulmonary hypertension. N. Engl. J. Med. 345, 367–371. (2001).
Tucker, A. & Rhodes, J. Role of vascular smooth muscle in the development of high altitude pulmonary hypertension: an interspecies evaluation. High Alt. Med. Biol. 2, 173–189. (2001).
MacLean, M.R., Hervé, P., Eddahibi, S. & Adnot, S. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br. J. Pharmacol. 131, 161–168. (2000).
Michelakis, E.D. & Weir, E.K. Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am. J. Med. Sci. 321, 292–299. (2001).
Egermayer, P., Town, G.I. & Peacock, A.J. Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax 54, 161–168. (1999).
Hervé, P. et al. Increased plasma serotonin in primary pulmonary hypertension. Am. J. Med. 99, 249–254 (1995).
Kéreveur, A. et al. High plasma serotonin levels in primary pulmonary hypertension: effect of long-term epoprostenol (Prostacyclin) therapy. Arterioscler. Thromb. Vasc. Biol. 20, 2233–2239 (2000).
Ullmer, C., Schmuck, K., Kalkman, H.O. & Lübbert, H. Expression of serotonin receptor mRNA in blood vessels. FEBS Lett. 370, 215–221 (1995).
Rich, S., Rubin, L., Walker, A.M., Schneeweiss, S. & Abenhaim, L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 117, 870–874 (2000).
Abenhaim, L. et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 335, 609–616. (1996).
Fitzgerald, L.W. et al. Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57, 75–81 (2000).
Launay, J.-M. et al. Ras involvement in signal transduction by the serotonin 5-HT2B receptor. J. Biol. Chem. 271, 3141–3147 (1996).
Nebigil, C.G., Launay, J.-M., Hickel, P., Tournois, C. & Maroteaux, L. 5-Hydroxytryptamine 2B receptor regulates cell-cycle progression: Cross talk with tyrosine kinase pathways. Proc. Natl. Acad. Sci. USA 97 2591–2596 (2000).
Ullmer, C., Boddeke, H.G.W.M., Schmuck, K. & Lübbert, H. 5-HT2B receptor-mediated calcium release from ryanodine-sensitive intracellular stores in human pulmonary artery endothelial cells. Br. J. Pharmacol. 117, 1081–1088 (1996).
Glusa, E. & Pertz, H.H. Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT2B receptors. Br. J. Pharmacol. 130, 692–698 (2000).
Nebigil, C.G. et al. Serotonin 2B receptor is required for heart development. Proc. Natl. Acad. Sci. USA 97, 9508–9513 (2000).
Nebigil, C.G. et al. Ablation of serotonin 5-HT2B receptors in mice leads to abnormal cardiac structure and function. Circulation 103, 2973–2979 (2001).
Bonhaus, D.W. et al. RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. Br. J. Pharmacol. 127, 1075–1082 (1999).
Belknap, J.K., Orton, E.C., Ensley, B., Tucker, A. & Stenmark, K.R. Hypoxia increases bromodeoxyuridine labeling indices in bovine neonatal pulmonary arteries. Am. J. Respir. Cell. Mol. Biol. 16, 366–371 (1997).
Rabinovitch, M. EVE and beyond, retro and prospective insights. Am. J. Physiol. 277, L5–12. (1999).
Vu, T.H. & Werb, Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 14, 2123–2133. (2000).
MacLean, M.R. Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action? Trends Pharmacol. Sci. 20, 490–495 (1999).
Eddahibi, S., Raffestin, B., Launay, J.M., Sitbon, M. & Adnot, S. Effect of dexfenfluramine treatment in rats exposed to acute and chronic hypoxia. Am. J. Respir. Crit. Care Med. 157, 1111–1119 (1998).
Eddahibi, S. et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. Invest. 105, 1555–1562 (2000).
Steudel, W. et al. Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3. J. Clin. Invest. 101, 2468–2477 (1998).
Hoshikawa, Y. et al. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am. J. Respir. Crit. Care Med. 164, 314–318. (2001).
Keegan, A., Morecroft, I., Smillie, D., Hicks, M.N. & MacLean, M.R. Contribution of the 5-HT1B receptor to hypoxia-induced pulmonary hypertension. Converging evidence using 5-HT1B-receptor knockout mice and the 5-HT1B/1D-receptor antagonist GR127935. Circ. Res. 89, 1231–1229 (2001).
Rabinovitch, M. Problems of pulmonary hypertension in children with congenital cardiac defects. Chest 93, 119S–126S. (1988).
Zhao, L., Long, L., Morrell, N.W. & Wilkins, M.R. NPR-A-Deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation 99, 605–607 (1999).
Buczko, W., De Gaetano, G. & Garattini, S. Effect of fenfluramine on 5-hydroxytryptamine uptake and release by rat blood platelets. Br. J. Pharmacol. 53, 563–359 (1975).
Rothman, R.B. et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836–2841. (2000).
Humbert, M. et al. Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis. Eur. Respir. J. 20, 59–65 (2002).
Naeije, R., Maggiorini, M., Delcroix, M., Leeman, M. & Melot, C. Effects of chronic dexfenfluramine treatment on pulmonary hemodynamics in dogs. Am. J. Respir. Crit. Care Med. 154, 1347–1350. (1996).
Eddahibi, S. et al. Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats. J. Pharmacol. Exp. Ther. 297, 148–154. (2001).
Eddahibi, S. et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest. 108, 1141–1150. (2001).
Rabinovitch, M. Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension. J. Clin. Invest. 108, 1109–1111. (2001).
Fanburg, B.L. & Lee, S.L. A new role for an old molecule: serotonin as a mitogen. Am. J. Physiol. 272, L795–806 (1997).
Lee, S.L., Wang, W.W., Finlay, G.A. & Fanburg, B.L. Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am. J. Physiol. 277, L282–291 (1999).
Pitt, B.R. et al. Serotonin increases DNA synthesis in rat proximal and distal pulmonary vascular smooth muscle cells in culture. Am. J. Physiol. 266, L178–186 (1994).
Sanchez, C. & Hyttel, J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 19, 467–489 (1999).
Cowan, K.N. et al. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nature Med. 6, 698–702 (2000).
Morrell, N.W. et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 104, 790–795. (2001).
Cowan, K.N., Jones, P.L. & Rabinovitch, M. Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ. Res. 84, 1223–1233. (1999).
Midha, K.K. et al. The identification of two new urinary metabolites of fenfluramine in man. Xenobiotica 13, 31–38. (1983).
Acknowledgements
We thank P. Hickel for technical assistance: J. Odillard for animal care: V. Mutel, Pr. J.-L. Laplanche and M. Mark for critical reading of the manuscript and for discussions: M. Pando and S. Brooks for English corrections: V. Mutel and D. McNamara for the gift of RS-127445: and F. Mentré and F. Godmard for statistical expertise. This work has been supported by funds from the Centre National de la Recherche Scientifique, the Institut National de la Santé et de la Recherche Médicale, the Hôpital Universitaire de Strasbourg and the Université Louis Pasteur, and by grants from the Fondation de France and the Association pour la Recherche contre le Cancer.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Launay, JM., Hervé, P., Peoc'h, K. et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8, 1129–1135 (2002). https://doi.org/10.1038/nm764
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm764
This article is cited by
-
Cardiovascular safety of psychedelic medicine: current status and future directions
Pharmacological Reports (2023)
-
Increased pulmonary serotonin transporter in patients with chronic obstructive pulmonary disease who developed pulmonary hypertension
European Journal of Nuclear Medicine and Molecular Imaging (2021)